Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions
GILD Stock Forecast
Gilead Sciences stock forecast is as follows: an average price target of $88.11 (represents a -3.61% downside from GILD’s last price of $91.41) and a rating consensus of 'Buy', based on 23 wall street analysts offering a 1-year stock forecast.
GILD Price Target
GILD Analyst Ratings
Buy
Gilead Sciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 07, 2024 | Joseph Catanzaro | Piper Sandler | $105.00 | $90.09 | 16.55% | 14.87% |
Oct 21, 2024 | Evan David Seigerman | BMO Capital | $94.00 | $86.11 | 9.16% | 2.83% |
Oct 21, 2024 | Andrew Berens | Leerink Partners | $96.00 | $86.72 | 10.70% | 5.02% |
Oct 18, 2024 | Terence Flynn | Morgan Stanley | $84.00 | $87.07 | -3.53% | -8.11% |
Sep 23, 2024 | Michael Yee | Jefferies | $95.00 | $83.76 | 13.42% | 3.93% |
Sep 12, 2024 | Salveen Richter | Goldman Sachs | $71.00 | $82.85 | -14.30% | -22.33% |
Sep 12, 2024 | Terence Flynn | Morgan Stanley | $79.00 | $82.63 | -4.39% | -13.58% |
Sep 11, 2024 | Joseph Catanzaro | Piper Sandler | $95.00 | $79.93 | 18.85% | 3.93% |
Aug 14, 2024 | Asthika Goonewardene | Truist Financial | $83.00 | $74.14 | 11.95% | -9.20% |
Aug 09, 2024 | Evan David Seigerman | BMO Capital | $85.00 | $75.59 | 12.45% | -7.01% |
Aug 09, 2024 | Brian Abrahams | RBC Capital | $72.00 | $75.59 | -4.75% | -21.23% |
Jul 08, 2024 | Steven Seedhouse | Raymond James | $93.00 | $67.76 | 37.25% | 1.74% |
Jun 24, 2024 | Michael Yee | Jefferies | $85.00 | $71.24 | 19.31% | -7.01% |
Jun 20, 2024 | Brian Skorney | Robert W. Baird | $80.00 | $69.21 | 15.59% | -12.48% |
Jun 17, 2024 | Salim Syed | Mizuho Securities | $90.00 | $64.52 | 39.50% | -1.54% |
Jun 14, 2024 | Brian Abrahams | RBC Capital | $74.00 | $64.68 | 14.41% | -19.05% |
May 20, 2024 | Evan David Seigerman | BMO Capital | $80.00 | $67.90 | 17.82% | -12.48% |
Apr 24, 2024 | Morten Herholdt | HSBC | $69.00 | $67.08 | 2.86% | -24.52% |
Feb 14, 2024 | Brian Abrahams | RBC Capital | $76.00 | $73.53 | 3.36% | -16.86% |
Sep 27, 2023 | Brian Abrahams | RBC Capital | $84.00 | $75.90 | 10.67% | -8.11% |
Sep 08, 2023 | Geoff Meacham | Bank of America Securities | $95.00 | $75.92 | 25.13% | 3.93% |
Feb 03, 2023 | Leerink Partners | $91.00 | $84.64 | 7.51% | -0.45% | |
Feb 03, 2023 | Piper Sandler | $112.00 | $81.39 | 37.61% | 22.52% | |
Jan 03, 2023 | Wells Fargo | $90.00 | $85.46 | 5.31% | -1.54% | |
Dec 01, 2022 | Morgan Stanley | $81.00 | $88.34 | -8.31% | -11.39% | |
Oct 31, 2022 | Carter Gould | Barclays | $76.00 | $79.27 | -4.13% | -16.86% |
Oct 28, 2022 | Robyn Karnauskas | Truist Financial | $91.00 | $70.20 | 29.63% | -0.45% |
Oct 28, 2022 | Brian Skorney | Robert W. Baird | $69.00 | $79.27 | -12.96% | -24.52% |
Sep 15, 2022 | Truist Financial | $76.00 | $64.81 | 17.26% | -16.86% | |
Sep 13, 2022 | Wells Fargo | $74.00 | $66.19 | 11.80% | -19.05% | |
Jul 15, 2022 | Morgan Stanley | $65.00 | $62.30 | 4.34% | -28.89% | |
May 23, 2022 | David Risinger | Leerink Partners | $68.00 | $64.04 | 6.18% | -25.61% |
May 17, 2022 | Do Kim | Piper Sandler | $69.00 | $63.18 | 9.21% | -24.52% |
Apr 29, 2022 | BMO Capital | $63.00 | $59.54 | 5.81% | -31.08% | |
Apr 29, 2022 | Piper Sandler | $73.00 | $60.04 | 21.59% | -20.14% | |
Apr 06, 2022 | Do Kim | Piper Sandler | $71.00 | $60.82 | 16.74% | -22.33% |
Mar 31, 2022 | Mohit Bansal | Wells Fargo | $63.00 | $59.45 | 5.97% | -31.08% |
Mar 01, 2022 | Michael Yee | Jefferies | $80.00 | $59.50 | 34.45% | -12.48% |
Feb 24, 2022 | Colin Bristow | UBS | $54.00 | $59.85 | -9.77% | -40.93% |
Feb 24, 2022 | Matthew Harrison | Morgan Stanley | $69.00 | $59.85 | 15.29% | -24.52% |
Feb 08, 2022 | Salim Syed | Mizuho Securities | $75.00 | $63.70 | 17.74% | -17.95% |
Feb 04, 2022 | Steve Chesney | Atlantic Equities | $62.00 | $63.10 | -1.74% | -32.17% |
Feb 03, 2022 | Jason McCarthy | Maxim Group | $84.00 | $64.57 | 30.09% | -8.11% |
Feb 03, 2022 | Hartaj Singh | Oppenheimer | $90.00 | $64.57 | 39.38% | -1.54% |
Jan 28, 2022 | David Toung | Argus Research | $75.00 | $67.99 | 10.31% | -17.95% |
Dec 06, 2021 | Salveen Richter | Goldman Sachs | $80.00 | $67.94 | 17.75% | -12.48% |
Nov 19, 2021 | Robert Driscoll | Wedbush | $67.00 | $67.14 | -0.21% | -26.70% |
Apr 29, 2021 | Cory Kasimov | J.P. Morgan | $74.00 | $61.14 | 21.03% | -19.05% |
Gilead Sciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 4 | 19 |
Avg Price Target | - | $94.75 | $84.53 |
Last Closing Price | $91.41 | $91.41 | $91.41 |
Upside/Downside | -100.00% | 3.65% | -7.53% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 13, 2024 | Citigroup | Buy | Initialise | |
Oct 21, 2024 | Barclays | Overweight | Overweight | Hold |
Oct 21, 2024 | Bernstein | Outperform | Outperform | Hold |
Oct 21, 2024 | Leerink Partners | Overweight | Overweight | Hold |
Oct 21, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
Oct 21, 2024 | RBC Capital | Underperform | Underperform | Hold |
Oct 21, 2024 | Leerink Partners | Outperform | Upgrade | |
Oct 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
Oct 17, 2024 | BMO Capital | Outperform | Outperform | Hold |
Oct 17, 2024 | Bernstein | Outperform | Initialise | |
Oct 07, 2024 | Wells Fargo | Sector Perform | Overweight | Upgrade |
Oct 07, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
Oct 04, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Sep 23, 2024 | Barclays | Positive | Positive | Hold |
Sep 23, 2024 | Jefferies | Buy | Buy | Hold |
Sep 20, 2024 | Needham | Hold | Hold | Hold |
Sep 12, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
Sep 12, 2024 | Morgan Stanley | Reduce | Reduce | Hold |
Sep 12, 2024 | BMO Capital | Outperform | Outperform | Hold |
Sep 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Sep 04, 2024 | Raymond James | Underperform | Underperform | Hold |
Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
Aug 15, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Aug 09, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
Jul 29, 2024 | Cantor Fitzgerald | Neutral | Neutral | Hold |
Jul 22, 2024 | Raymond James | Underperform | Underperform | Hold |
Jul 22, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Jul 08, 2024 | Raymond James | Outperform | Upgrade | |
Jun 24, 2024 | Jefferies | Buy | Buy | Hold |
Jun 20, 2024 | BMO Capital | Outperform | Outperform | Hold |
Jun 14, 2024 | UBS | Sector Perform | Sector Perform | Hold |
Jun 14, 2024 | RBC Capital | Underperform | Underperform | Hold |
Jun 14, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Jun 14, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
May 20, 2024 | BMO Capital | Outperform | Outperform | Hold |
Apr 24, 2024 | HSBC | Hold | Upgrade | |
Apr 19, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
Feb 14, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Sep 27, 2023 | BMO Capital | Outperform | Market Perform | Downgrade |
Sep 08, 2023 | Bank of America Securities | Buy | Upgrade | |
May 16, 2023 | BMO Capital | Market Perform | Outperform | Upgrade |
Mar 10, 2023 | RBC Capital | Sector Perform | Sector Perform | Hold |
Feb 14, 2023 | Benchmark | Buy | Buy | Hold |
Feb 03, 2023 | SVB Leerink | Market Perform | Market Perform | Hold |
Feb 03, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Feb 03, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Jan 03, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Jan 03, 2023 | RBC Capital | Sector Perform | Downgrade | |
Dec 08, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Dec 01, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Nov 01, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Oct 28, 2022 | Wedbush | Outperform | Initialise | |
Oct 28, 2022 | Needham | Hold | Hold | Hold |
Oct 28, 2022 | Piper Sandler | Neutral | Overweight | Upgrade |
Oct 05, 2022 | J.P. Morgan | Buy | Overweight | Upgrade |
Oct 04, 2022 | Credit Suisse | Outperform | Upgrade | |
Oct 04, 2022 | Needham | Hold | Initialise | |
Oct 04, 2022 | J.P. Morgan | Buy | Upgrade | |
Sep 13, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Jul 26, 2022 | Piper Sandler | Neutral | Neutral | Hold |
Jul 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
May 23, 2022 | SVB Leerink | Market Perform | Initialise | |
May 17, 2022 | Piper Sandler | Neutral | Neutral | Hold |
Apr 29, 2022 | BMO Capital | Market Perform | Market Perform | Hold |
Apr 21, 2022 | Cowen & Co. | Outperform | Outperform | Hold |
Apr 06, 2022 | Piper Sandler | Neutral | Neutral | Hold |
Mar 31, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Feb 28, 2022 | BMO Capital | Market Perform | Downgrade | |
Feb 26, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Feb 08, 2022 | Mizuho Securities | Buy | Buy | Hold |
Gilead Sciences Financial Forecast
Gilead Sciences Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $7.12B | $7.05B | $6.60B | $6.35B | $7.39B | $7.04B | $6.26B | $6.59B | $7.24B | $7.42B | $6.22B | $6.42B | $7.42B | $6.58B | $5.14B | $5.55B | $5.88B | $5.60B | $5.68B | $5.28B | $5.09B | $6.50B |
Avg Forecast | $7.56B | $7.30B | $6.87B | $6.66B | $7.16B | $7.02B | $6.70B | $6.36B | $7.10B | $6.81B | $6.45B | $6.33B | $6.64B | $6.13B | $5.86B | $6.29B | $6.61B | $6.29B | $6.08B | $6.74B | $7.08B | $6.29B | $5.29B | $5.45B | $5.72B | $5.61B | $5.53B | $5.30B | $5.74B | $6.65B |
High Forecast | $7.75B | $7.49B | $7.05B | $6.75B | $7.43B | $7.05B | $6.70B | $6.36B | $7.27B | $7.02B | $6.62B | $6.49B | $6.85B | $6.13B | $5.86B | $6.29B | $6.61B | $6.29B | $6.08B | $6.74B | $7.08B | $6.29B | $5.29B | $5.45B | $5.72B | $5.61B | $5.53B | $5.30B | $6.89B | $7.98B |
Low Forecast | $7.39B | $7.14B | $6.72B | $6.58B | $6.93B | $6.98B | $6.70B | $6.36B | $6.89B | $6.63B | $6.31B | $6.19B | $6.42B | $6.13B | $5.86B | $6.29B | $6.61B | $6.29B | $6.08B | $6.74B | $7.08B | $6.29B | $5.29B | $5.45B | $5.72B | $5.61B | $5.53B | $5.30B | $4.59B | $5.32B |
# Analysts | 3 | 3 | 3 | 5 | 15 | 7 | 9 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.02% | 1.00% | 1.11% | 1.15% | 1.07% | 1.05% | 1.10% | 1.18% | 1.02% | 0.95% | 1.05% | 1.05% | 0.97% | 1.02% | 1.03% | 1.00% | 1.03% | 1.00% | 0.89% | 0.98% |
Forecast
Gilead Sciences EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 15 | 7 | 9 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
EBITDA | - | - | - | - | - | - | - | - | $1.61B | $2.62B | $1.67B | $2.01B | $2.42B | $3.11B | $2.08B | $86.00M | $1.53B | $4.23B | $2.69B | $3.06B | $2.57B | $2.59B | $2.14B | $2.59B | $2.49B | $-904.00M | $3.01B | $2.96B | $2.68B | $4.17B |
Avg Forecast | $2.47B | $2.38B | $2.24B | $2.17B | $2.33B | $2.29B | $2.19B | $619.71M | $2.32B | $2.22B | $2.10B | $563.37M | $2.38B | $2.18B | $2.08B | $512.15M | $2.35B | $2.24B | $2.16B | $3.02B | $2.52B | $2.23B | $1.88B | $2.44B | $2.03B | $1.99B | $1.97B | $2.69B | $2.98B | $4.27B |
High Forecast | $2.53B | $2.44B | $2.30B | $2.20B | $2.42B | $2.30B | $2.19B | $743.65M | $2.37B | $2.29B | $2.16B | $676.04M | $2.86B | $2.18B | $2.08B | $614.59M | $2.35B | $2.24B | $2.16B | $3.62B | $2.52B | $2.23B | $1.88B | $2.93B | $2.03B | $1.99B | $1.97B | $3.23B | $3.58B | $5.12B |
Low Forecast | $2.41B | $2.33B | $2.19B | $2.14B | $2.26B | $2.28B | $2.19B | $495.77M | $2.25B | $2.16B | $2.06B | $450.70M | $1.91B | $2.18B | $2.08B | $409.72M | $2.35B | $2.24B | $2.16B | $2.41B | $2.52B | $2.23B | $1.88B | $1.95B | $2.03B | $1.99B | $1.97B | $2.15B | $2.39B | $3.41B |
Surprise % | - | - | - | - | - | - | - | - | 0.70% | 1.18% | 0.79% | 3.57% | 1.01% | 1.43% | 1.00% | 0.17% | 0.65% | 1.89% | 1.24% | 1.01% | 1.02% | 1.16% | 1.14% | 1.06% | 1.23% | -0.45% | 1.53% | 1.10% | 0.90% | 0.98% |
Forecast
Gilead Sciences Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 15 | 7 | 9 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
Net Income | - | - | - | - | - | - | - | - | $1.43B | $2.18B | $2.14B | $1.01B | $1.64B | $1.79B | $1.14B | $12.00M | $376.00M | $2.59B | $1.52B | $1.73B | $1.55B | $360.00M | $-3.35B | $1.55B | $2.70B | $-1.17B | $1.88B | $1.98B | $1.54B | $2.70B |
Avg Forecast | $2.69B | $2.60B | $2.29B | $2.20B | $2.15B | $1.92B | $2.02B | $19.05M | $2.21B | $2.40B | $2.06B | $17.32M | $592.24M | $1.78B | $1.90B | $15.75M | $1.99B | $2.20B | $2.18B | $1.74B | $2.55B | $2.44B | $1.81B | $1.45B | $2.09B | $2.18B | $2.15B | $1.79B | $1.71B | $2.76B |
High Forecast | $2.78B | $2.69B | $2.36B | $2.29B | $2.56B | $1.96B | $2.02B | $22.86M | $2.56B | $2.62B | $2.13B | $20.78M | $710.69M | $1.78B | $1.90B | $18.90M | $1.99B | $2.20B | $2.18B | $2.08B | $2.55B | $2.44B | $1.81B | $1.74B | $2.09B | $2.18B | $2.15B | $2.15B | $2.06B | $3.31B |
Low Forecast | $2.61B | $2.53B | $2.22B | $2.15B | $1.46B | $1.88B | $2.01B | $15.24M | $1.99B | $2.15B | $2.00B | $13.86M | $473.80M | $1.78B | $1.90B | $12.60M | $1.99B | $2.20B | $2.18B | $1.39B | $2.55B | $2.44B | $1.81B | $1.16B | $2.09B | $2.18B | $2.15B | $1.43B | $1.37B | $2.21B |
Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.91% | 1.04% | 58.31% | 2.77% | 1.00% | 0.60% | 0.76% | 0.19% | 1.18% | 0.70% | 1.00% | 0.61% | 0.15% | -1.85% | 1.07% | 1.29% | -0.54% | 0.87% | 1.10% | 0.90% | 0.98% |
Forecast
Gilead Sciences SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 15 | 7 | 9 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
SG&A | - | - | - | - | - | - | - | - | $1.61B | $1.31B | $1.85B | $1.32B | $2.02B | $1.21B | $1.36B | $1.08B | $1.65B | $1.19B | $1.35B | $1.05B | $1.73B | $1.11B | $1.24B | $1.08B | $1.20B | $1.05B | $1.09B | $1.03B | $997.00M | $850.00M |
Avg Forecast | $1.56B | $1.50B | $1.41B | $1.37B | $1.47B | $1.44B | $1.38B | $1.09B | $1.46B | $1.40B | $1.33B | $987.27M | $2.56B | $1.26B | $1.20B | $897.51M | $1.36B | $1.29B | $1.25B | $1.06B | $1.45B | $1.29B | $1.09B | $1.01B | $1.17B | $1.15B | $1.14B | $934.04M | $1.11B | $868.64M |
High Forecast | $1.60B | $1.54B | $1.45B | $1.39B | $1.53B | $1.45B | $1.38B | $1.30B | $1.50B | $1.44B | $1.36B | $1.18B | $3.07B | $1.26B | $1.20B | $1.08B | $1.36B | $1.29B | $1.25B | $1.27B | $1.45B | $1.29B | $1.09B | $1.21B | $1.17B | $1.15B | $1.14B | $1.12B | $1.33B | $1.04B |
Low Forecast | $1.52B | $1.47B | $1.38B | $1.35B | $1.43B | $1.44B | $1.38B | $868.79M | $1.42B | $1.36B | $1.30B | $789.81M | $2.05B | $1.26B | $1.20B | $718.01M | $1.36B | $1.29B | $1.25B | $848.04M | $1.45B | $1.29B | $1.09B | $806.32M | $1.17B | $1.15B | $1.14B | $747.23M | $888.34M | $694.91M |
Surprise % | - | - | - | - | - | - | - | - | 1.10% | 0.94% | 1.39% | 1.34% | 0.79% | 0.96% | 1.13% | 1.21% | 1.21% | 0.92% | 1.08% | 1.00% | 1.19% | 0.86% | 1.14% | 1.07% | 1.03% | 0.91% | 0.96% | 1.10% | 0.90% | 0.98% |
Forecast
Gilead Sciences EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 15 | 7 | 9 | 9 | 10 | 21 | 10 | 10 | 13 | 9 | 9 | 16 | 10 | 10 | 19 | 13 | 10 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 15 |
EPS | - | - | - | - | - | - | - | - | $1.15 | $1.75 | $1.71 | $0.81 | $1.31 | $1.43 | $0.91 | $0.01 | $0.30 | $2.06 | $1.21 | $1.38 | $1.24 | $0.29 | $-2.67 | $1.23 | $2.13 | $-0.92 | $1.48 | $1.55 | $1.18 | $2.07 |
Avg Forecast | $2.15 | $2.08 | $1.82 | $1.75 | $1.72 | $1.53 | $1.61 | $-1.49 | $1.76 | $1.92 | $1.64 | $1.52 | $1.52 | $1.43 | $1.52 | $1.80 | $1.59 | $1.76 | $1.74 | $2.08 | $2.04 | $1.95 | $1.44 | $1.57 | $1.67 | $1.74 | $1.72 | $1.61 | $1.86 | $2.33 |
High Forecast | $2.22 | $2.14 | $1.88 | $1.83 | $2.04 | $1.56 | $1.61 | $-1.45 | $2.04 | $2.09 | $1.70 | $1.57 | $1.58 | $1.43 | $1.52 | $1.80 | $1.59 | $1.76 | $1.74 | $2.08 | $2.04 | $1.95 | $1.44 | $1.57 | $1.67 | $1.74 | $1.72 | $1.61 | $2.23 | $2.80 |
Low Forecast | $2.08 | $2.01 | $1.77 | $1.71 | $1.16 | $1.50 | $1.61 | $-1.54 | $1.59 | $1.72 | $1.59 | $1.48 | $1.45 | $1.43 | $1.52 | $1.80 | $1.59 | $1.76 | $1.74 | $2.08 | $2.04 | $1.95 | $1.44 | $1.57 | $1.67 | $1.74 | $1.72 | $1.61 | $1.49 | $1.86 |
Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.91% | 1.04% | 0.53% | 0.86% | 1.00% | 0.60% | 0.01% | 0.19% | 1.17% | 0.70% | 0.66% | 0.61% | 0.15% | -1.85% | 0.78% | 1.28% | -0.53% | 0.86% | 0.96% | 0.63% | 0.89% |
Forecast
Gilead Sciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
MRK | Merck | $99.14 | $135.83 | 37.01% | Buy |
AZN | AstraZeneca | $66.25 | $88.00 | 32.83% | Buy |
LLY | Eli Lilly and | $781.98 | $1.03K | 31.39% | Buy |
AMGN | Amgen | $261.22 | $338.22 | 29.48% | Buy |
PFE | Pfizer | $26.59 | $32.71 | 23.02% | Hold |
JNJ | Johnson & Johnson | $144.19 | $175.13 | 21.46% | Buy |
ABBV | AbbVie | $181.22 | $211.20 | 16.54% | Buy |
GILD | Gilead Sciences | $91.41 | $88.11 | -3.61% | Buy |
BMY | Bristol-Myers Squibb | $56.57 | $50.50 | -10.73% | Hold |